ESPR
Esperion Therapeutics Inc
NASDAQ · Pharmaceuticals
$3.40
+0.22 (+6.92%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 424.43M | 262.25M | 131.25M | 122.60M | 119.77M |
| Net Income | -66,077,135 | -36,745,811 | 36.94M | 36.77M | 36.24M |
| EPS | — | — | — | — | — |
| Profit Margin | -15.6% | -14.8% | 28.2% | 30.0% | 30.3% |
| Rev Growth | +61.8% | +61.8% | -8.2% | -8.9% | +18.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 290.34M | 272.00M | 279.82M |
| Total Equity | — | — | 513.38M | 501.71M | 541.43M |
| D/E Ratio | — | — | 0.57 | 0.54 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -47,812 | -28,065 | 70.25M | 61.92M | 62.84M |
| Free Cash Flow | — | — | 44.11M | 30.39M | 39.08M |